aTyr Pharma Q2 cash $44.1M; sarcoidosis data readout expected mid-September

aTYR PHARMA INC

2022-Q2 EPS reported -$1.16

Cash, equivalents and investments $44.1M as of June 30, 2021; R&D expense $7.7M, G&A $2.8M.
Last patient visit completed in Phase 1b/2a study of ATYR1923 in pulmonary sarcoidosis; data due mid-September 2021.
Kyorin completed Phase 1 study of ATYR1923 in 32 Japanese volunteers; safe, well-tolerated, PK consistent.
Appointed Sara Zaknoen, M.D. to board; received US patent for ATYR1923 lung inflammation methods.
Shares outstanding 16.9M as of Aug 9, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.